Abstract Deep vein thrombosis and pulmonary embolism are common diseases with significant morbidity and mortality. Clinical probability assessment reliably identifies low-risk patients, and when paired with a negative D-dimer test, safely excludes venous thromboembolism. Compression ultrasonography confirms the diagnosis of deep vein thrombosis, whereas computed tomography pulmonary angiography is typically used to confirm pulmonary embolism. Risk assessment of acute pulmonary embolism stratifies low-risk patients for outpatient treatment, and high-risk patients for consideration of thrombolytic therapy. The recent approval of rivaroxaban, a novel oral anticoagulant, can simplify and expedite treatment in select patients. Ongoing clinical trials may uncover methods to prevent postthrombotic syndrome and chronic thromboembolic pulmonary hypertension. In this report, we review current diagnostic and management methods for deep vein thrombosis and pulmonary embolism.
Introduction
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of cardiovascular mortality in the USA, responsible for nearly 550,000 hospitalizations annually, with DVT accounting for 60 % of these events [1] . The 30-day mortality rate for PE is 8.2 % with treatment and 20 % with recurrent events [2] . Improved diagnostic techniques recently demonstrated one third of patients with DVT also have occult PE [3, 4] . In addition to disease burden, VTE also carries a significant financial burden for patients and the health care system. In patients with VTE, the 1-year cost is estimated to be $33,531, nearly twice that for matching controls [1] .
The cornerstone of VTE treatment remains anticoagulation, which carries a considerable 3-month bleeding risk of 2.1-12.8 % [2, 5 •• , 6] . The difficulty lies in creating effective diagnostic and treatment strategies that detect VTE without placing patients at undue risk. This review outlines current diagnostic and management strategies for DVT and PE, focusing on established practices and the ever-changing landscape of this disease.
Diagnosis

Deep Vein Thrombosis
Limb swelling, pain, warmth, and erythema can all prompt DVT evaluation. Unfortunately, clinical assessment alone cannot accurately identify DVT [7] . Of all patients evaluated for DVT, only about 20 % have the disease [5 •• ] . Therefore, clinicians rely on multiple diagnostic methods, including clinical scoring systems, laboratory assays, and noninvasive imaging.
Current Diagnostic Algorithm
The University of Utah's evidence-based approach to DVT diagnosis is depicted in Fig. 1 . This algorithm was derived from high-level studies, including risk prediction models, laboratory analysis, and different imaging modalities [contrast venography, two-point compression ultrasonography, whole-leg ultrasonography, computed tomography venography (CTV), and magnetic resonance venography (MRV)]. The components of this algorithm are based on influential reviews and consensus statements, including the current American College of Chest Physicians guidelines [5 •• , 8, 9, 10, 11] . This algorithm combines pretest probability assessment with validated diagnostic methods to accurately diagnose or exclude DVT. A discussion of how this algorithm has evolved into our current approach and evolving issues including distal lower extremity DVT, upper extremity DVT (UEDVT), and bedside ultrasonography follows.
Clinical Scoring Systems
Although other scoring systems have been developed, the Wells score remains the most commonly used and widely validated method [12] . The simplified Wells score is illustrated in the text box in Fig. 1 [13] . A limitation of this scoring system is its reliance on the subjectivity of determining whether an alternative diagnosis is more or less likely than DVT. The initial diagnostic step is determination of DVT likelihood (Fig. 1) . A score of 2 or greater indicates that DVT is likely and requires imaging, whereas a score less than 2 indicates DVT is unlikely, and one should test for D-dimer as the next step [13] .
D-Dimer
D-dimer is a fibrin degradation product and its level is typically elevated in the presence of VTE [14] . However, the level of D-dimer is elevated in several clinical conditions, including infection, inflammation, cancer, surgery, trauma, burns, coronary artery disease, stroke, and pregnancy, limiting its positive predictive value [14] . Multiple D-dimer assays are available, with the highly sensitive D-dimer assays (ELISAs) demonstrating the best clinical utility [15] . For diagnosis of DVT, the D-dimer result must be combined with a clinical scoring system (Wells score) and ultrasonography, if indicated [13] (Fig. 1) . Most importantly, a low pretest probability and a negative D-dimer test can safely exclude DVT without the need for imaging. A positive D-dimer test in patients with low pretest probability requires further evaluation before a diagnosis can be determined.
Imaging
Noninvasive compression ultrasonography (CUS) has essentially replaced contrast venography as the gold standard for diagnosis of DVT [16] . Two-point CUS, evaluating the common femoral and popliteal veins, has been extensively studied and widely adopted, despite being unable to detect distal DVT (calf vein) [17] [18] [19] (see the related article in this issue by Baird et al.) Up to 20 % of distal DVTs propagate proximally in 1-2 weeks, necessitating serial CUS examinations [20] . Whole-leg CUS was later developed to detect proximal and distal DVT in a single study. The safety of this approach was demonstrated in a recent systematic review and meta-analysis for all patients, except those with the highest pretest probability [21] . A follow-up prospective study of high pretest probability patients with a negative whole-leg CUS result showed a similarly low VTE event rate of 0.6 % at 3 months [22 •• ] . On the basis of these results, whole-leg CUS is preferred over two-point CUS as it can safely exclude DVT in a single study. When whole-leg CUS is unavailable, an initial high pretest probability and negative two-point CUS result would require D-dimer testing and, if positive, another CUS examination in 1-2 weeks (Fig. 1) . Other imaging modalities, including CTV [23] , MRV [24, 25] , and nuclear medicine scintigraphy [26, 27] , may have benefits over CUS in select patients, but require additional study prior to being incorporated into routine DVT evaluation.
Distal DVT
Distal DVT is more commonly associated with transient risk factors and a lower risk of PE compared to proximal DVT. Some distal DVTs resolve without therapy, leading some clinicians to question their significance [28 •• ] . However, in high-risk patients, 15-20 % of distal DVTs will extend proximally, necessitating treatment [28 •• , 29] . The increasing use of whole-leg CUS is likely attributing to more frequent diagnosis of distal DVT, and potentially unnecessary therapy.
Upper Extremity DVT UEDVT refers to subclavian, axillary, or brachial vein thrombosis, and constitutes 4-10 % of all VTE. The frequent use of central venous catheters and cardiac devices may be responsible for the increasing prevalence of UEDVT [11, 30] . Patients with UEDVT are more likely to be younger and thinner, and are at lower risk of PE (8 vs. 31 %) [31] . The literature on UEDVT is less extensive than that on lower extremity DVT, with insufficient data to guide management [5 •• ] . D-dimer has not been studied prospectively in UED-VT, and a negative ultrasonography result in a patient with high clinical suspicion is insufficient to exclude this diagnosis [30] . Therefore, high clinical suspicion with a negative CUS result warrants further evaluation. Contrast venography remains the gold standard [30] . CTV and MRV are less invasive than contrast venography, but there is insufficient evidence to justify widespread adoption of these imaging modalities [9] .
Bedside Ultrasonography
Ultrasonography is becoming ubiquitous in emergency departments and more frequently available in hospitals for bedside use. There is considerable interest from clinicians to implement this technology for the prompt evaluation of suspected DVT. Emergency and critical care physicians can reliably diagnose DVT using bedside ultrasonography after a brief training program [32 
A recent metaanalysis of CUS performed in the emergency department for DVT showed 94.8 % sensitivity and 96.2 % specificity [34] . These studies demonstrate that a treating clinician can promptly diagnose and initiate DVT therapy, although further study is needed to validate this approach [34] .
Pulmonary Embolism
Chest pain, shortness of breath, tachycardia, tachypnea, hypoxia, syncope, and hemoptysis can all be presenting signs and symptoms of PE. Much like DVT, the clinical presentation alone is insufficient to diagnose or exclude PE [35] . The diagnostic algorithm for PE is similar to that for DVT, as it incorporates clinical assessment, D-dimer testing, and imaging.
Current Diagnostic Algorithm
The University of Utah's evidence-based approach to PE diagnosis is outlined in Fig. 2 . This approach combines a clinical scoring system with D-dimer testing and imaging, consistent with consensus guidelines [9, 36 • ]. The landmark study that reshaped PE diagnostics was the Christopher Study, which used a dichotomized Wells score with D-dimer testing and computed tomography pulmonary angiography (CTPA) to identify patients in whom PE was unlikely and anticoagulation could be safely withheld [37] .
Clinical Scoring Systems
The Wells score for PE is the most used and best validated scoring system [38] . The current PE-specific Wells score uses a dichotomized score similar to the DVT scoring system, but relies on different clinical characteristics [37] . It has been criticized for the heavily weighted clinician assessment of ''alternative diagnosis less likely than PE,'' which introduces a significant subjective component to the score. Regardless, the robust supporting evidence and ease of calculation make this scoring system the initial step for objectively assessing pretest probability for suspected PE.
The pulmonary embolism rule-out criteria (PERC) is an alternative method for pretest probability assessment in low-risk patients, as determined either by Wells criteria or by physician gestalt [39] . When all components of the rule are satisfied (low risk of PE, age less than 50 years, oxygen saturation 95 % or greater, pulse rate below 100 beats per minute, no hemoptysis, no estrogen use, no hospitalization within 4 weeks for surgery/trauma, no prior VTE, and no unilateral leg swelling) the probability of VTE is less than 2 % [38] . A recent meta-analysis of PERC estimated the pooled negative likelihood ratio to be 0.18 [95 % 
D-Dimer
Mirroring DVT evaluation, D-dimer assessment is useful when the pretest probability is low and the result is negative, effectively ruling out PE [37] . The same limitations of D-dimer assays apply to D-dimer assessment in PE as well. Importantly, a negative D-dimer result cannot solely exclude the diagnosis of PE when the pretest probability is likely. Approximately 10 % of patients with likely clinical probability and negative D-dimer result who were not anticoagulated suffered a VTE event [41] . Because the D-dimer test is not reliable enough to exclude PE in a patient with high likelihood, testing in such patients should begin with imaging ( Fig. 2) .
Imaging
CTPA has become the imaging modality of choice for PE diagnosis, essentially replacing the previous gold standard, pulmonary angiography [23, 37, 42] . When compared with ventilation-perfusion scanning, CTPA is noninferior and often provides alternative nonthrombotic diagnoses [42] . Prospective studies demonstrate low VTE event rates (0.27-1.3 %) after a negative study [37, 43 •• ]. The aforementioned studies offer considerable evidence to justify CTPA, combined with D-dimer testing and a clinical scoring system, as the standard of care for PE diagnosis. A negative CTPA result can safely exclude the diagnosis of PE (Fig. 2) .
CTPA carries risks of radiation exposure, contrast allergies, and contrast-induced nephropathy. For these reasons, other imaging modalities remain relevant in PE diagnosis. Ventilation-perfusion scanning, originally compared with conventional pulmonary angiography in the PIOPED study [44] , is reliable when combined with a clinical prediction model in patients with high or low probability scans. Unfortunately, scans are frequently of intermediate probability, requiring further diagnostic testing [42] . A patient with a normal chest X-ray may benefit from ventilation-perfusion scanning, given the decreased radiation exposure and fewer adverse effects compared with CTPA, if imaging is indicated [42] .
Alternative imaging methods for PE include echocardiography [45] , specialized nuclear medicine scans [ 
PE Risk Stratification
Acute PE is associated with a nearly fourfold increase in mortality compared with DVT [52] . Prompt risk stratification is essential during initial management, as prognosis depends on patient characteristics and clinical presentation [53] . Pulmonary emboli should be stratified into one of three risk categories-massive, submassive, or low-riskaccording to hemodynamic stability and evidence of right ventricular (RV) dysfunction [54 Submassive PE, defined as an acute PE with evidence of RV dysfunction and without arterial hypotension, carries a mortality rate of 3-15 % [58] . The presence of RV dysfunction appears to be associated with worse outcomes [59] . Several diagnostic techniques can identify RV dysfunction, including imaging, cardiac biomarkers, and electrocardiography [60] . Although the risk of RV failure is lower with submassive PE, identification of these patients is important to monitor them for early clinical deterioration and consideration of thrombolytic therapy [56 
Clinical Scoring Systems
The use of validated risk-prediction tools, such as the PE severity index [64] , Geneva score [65] , simplified PE severity index [66] [67] recently examined the combination of troponin T with the simplified PE severity index and demonstrated an increased ability to identify these low-risk patients. Future risk prediction models may rely on similar amalgamations of clinical assessment, biomarkers, and imaging.
Imaging
Noninvasive imaging modalities, including CTPA, echocardiography, and CUS, have been extensively studied, with conflicting results. CTPA is appealing as it can simultaneously diagnose PE and demonstrate RV dilation. Several studies suggest RV dilation on computed tomography is a predictor of adverse outcomes [68] [69] [70] . However, recent meta-analyses failed to substantiate these findings because of methodological diversity and limited prognostic value, questioning its utility for risk stratification [59, 71] .
In addition to RV dilation, echocardiography can identify interventricular septal bowing, pulmonary arterial hypertension, and RV hypokinesis not identified by computed tomography [53, 72] . Normal RV function conveys a high negative predictive value (98 %) for all-cause mortality, PE-related mortality, and serious adverse events [ [73, 74] .
The utility of lower extremity DVT assessment at the time of PE diagnosis remains undetermined. Early studies failed to demonstrate a correlation between concurrent PE and DVT and mortality [72, 75] . Recently, a study demonstrated concurrent DVT is associated with increased mortality [ Further studies are needed to assess whether routine DVT screening at the time of PE diagnosis is cost-effective, or warrants additional therapy (thrombolytics or inferior vena caval filter).
Biomarkers
Several biomarkers have been evaluated for PE risk stratification [77] [78] [79] . Eleveation of the levels of troponin T and troponin I elevations can identify patients with submassive PE at increased risk of adverse outcomes (odds ratio 4.12) and mortality (odds ratio 5.90) [80] . Similarly, brain natriuretic peptide (BNP) and N-terminal pro-BNP can predict adverse events [59, 81] . A novel biomarker, growth differentiation factor 15, outperformed troponin T and N-terminal pro-BNP with respect to risk prediction of PE-related complications, deserving further study [82] . Cardiac biomarkers can supplement risk stratification in PE, although sufficient predictive value to independently guide thrombolytic therapy is lacking [56 •• ] .
Plasma Lactate
Investigators from Florence, Italy, recently showed an increased plasma lactate level of 2 mmol/L or greater in patients with PE was associated with an increased risk of death (HR 11.67; 95 % CI 3.32-41.03) [83] . This increased risk was independent of shock, RV dysfunction, or elevation of troponin I levels. Further study is needed to validate the role of elevated plasma lactate levels in PE risk stratification.
Initial Antithrombotic Therapy
The necessity of initial parenteral anticoagulation for DVT treatment has long been established [84] . In patients with normal renal function, unfractionated heparin (UFH) has largely been replaced by low molecular weight heparin (LMWH) and fondaparinux because of lower cost, lack of requisite laboratory monitoring, and favorable safety and efficacy profiles [85, 86 • ]. Meta-analysis of nearly 9,000 patients found LMWH superior to UFH with regard to allcause mortality, recurrent VTE, and major bleeding [87] . Fondaparinux demonstrated similar efficacy and safety profiles compared with LMWH, and superiority to UFH [ Upper Extremity DVT Management of UEDVT has not been as rigorously investigated as management of lower extremity DVT and PE [30] . At the time of writing, no randomized controlled therapeutic trials have been published. Retrospective and observational studies have demonstrated good outcomes with antithrombotic therapy [88, 89] . On the basis of available evidence and lower extremity DVT experience, a similar treatment strategy is recommended [30, 56 •• ]. This strategy consists of parenteral anticoagulation for a minimum of 5 days, and concurrent VKA administration. LMWHs are the preferred parenteral agents, except in patients with renal insufficiency, in whom UFH is suggested [90] . Discontinuation of use of central venous catheters is not essential if there is an ongoing need for the catheter and it remains functional [30, 56 •• ].
Pulmonary Embolism
Prompt risk stratification of acute PE is essential to guide initial management. Massive PE warrants systemic thrombolytic therapy, catheter-assisted thrombolysis in patients with contraindications to systemic thrombolytic therapy, or surgical thrombectomy. Submassive and lowrisk PE therapy begins with parenteral anticoagulation for a minimum of 5 days and concurrent VKA administration. Generally, LMWHs are superior to UFH infusion, allowing early hospital discharge or outpatient therapy in low-risk patients [ 
Maintenance Antithrombotic Therapy
Maintenance therapy for UEDVT, lower extremity DVT, and PE is nearly identical. After an initial course of parenteral anticoagulation, maintenance antithrombotic therapy for at least 3 months is essential to prevent thrombus extension and recurrence. The decision to continue longterm therapy (beyond the first 3 months) should be individualized, dependent on patient-specific VTE-risk and bleeding-risk factors. Oral VKAs remain fundamental to maintenance therapy, despite their multiple limitations, such as narrow therapeutic window, requisite laboratory monitoring, myriad drug-drug and dietary interactions, and variable metabolism [56 •• , 84] . The intricacies of oral VKA management are beyond the scope of this review. Fortunately, advances in antithrombotic therapy are occurring. Registry data demonstrate minimal mortality benefit of thrombolytics in submassive PE (less than 1 %) [ 
Novel Oral Anticoagulants
Adjunctive thrombolytic therapy may confer some benefit over anticoagulation alone; potentially decreasing the development of chronic thromboembolic pulmonary hypertension and resulting in improvement in RV systolic pressure, RV function, 6-min walk test result, and New York Heart Association classification [94 • , 95, 96] . Additional studies are ongoing to further assess the benefits of thrombolytics in submassive PE [97, 98] .
Deep Vein Thrombosis
Systemic thrombolytics demonstrate greater thrombus reduction and fewer postthrombotic syndrome symptoms compared with anticoagulation alone [99] . However, major bleeding events (14 vs. 4 %) outweigh the benefits of systemic administration [54 •• ] . In patients with severe symptoms or limb-threatening DVT (i.e., phlegmasia cerulea dolens), catheter-assisted thrombolysis is appropriate. Prior evidence on catheter-assisted thrombolysis demonstrated reductions in residual thrombus and postthrombotic syndrome symptoms, although the rate of major bleeding remained high (up to 11 %) [100] . Recently Enden et al. [101] used a low-dose fibrinolytic regimen, with similar efficacy and fewer major bleeding events (2.0 %). A prospective trial comparing pharmacomechanical thrombolysis with anticoagulation alone for the prevention of postthrombotic syndrome is ongoing [102] .
Conclusions
DVT and PE are common diseases, and are associated with significant morbidity and mortality. Clinical probability assessment with a validated risk prediction tool and adherence to diagnostic algorithms can expedite accurate diagnosis and treatment. Combining clinical assessment with a highly sensitive D-dimer test in certain populations can safely exclude VTE, reducing the use of unnecessary imaging studies. Prompt risk stratification of PE is important to identify patients eligible for outpatient therapy, or those requiring thrombolytic therapy. Novel oral anticoagulants, in properly selected patients, offer alternatives to standard therapy. Ongoing trials involving thrombolytic therapy for submassive PE and catheter-assisted thrombolysis for DVT may demonstrate reductions in the number of thromboembolic complications. CYP3A4 cytochrome P450 3A4, P-gp P-glycopeptide, VTE venous thromboembolism, TKA total knee arthroplasty, THA total hip arthroplasty, FDA Food and Drug Administration a Potent combined CYP3A4 and P-gp inhibitors include ketoconazole, ritonavir, clarithromycin, erythromycin, and fluconazole; combined CYP3A4 and P-gp inducers include carbamazepine, phenytoin, rifampin, and St. John's wort b Potent P-gp inhibitors include verapamil, amiodarone, quinidine, and clarithromycin c Initial dosing in VTE treatment is twice daily for 3 weeks, followed by once daily. VTE prophylaxis and stroke prophylaxis dosing is once daily
